U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation
Posted in BioUtah News
Tagged teva pharmaceuticals
Comments Off on U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.
Posted in BioUtah News
Tagged teva pharmaceuticals
Comments Off on Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
The Teva Turnaround: Steering a Company Comeback
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.
Posted in BioUtah News
Tagged teva pharmaceuticals
Comments Off on The Teva Turnaround: Steering a Company Comeback
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics. The program, launching this month, will run for a minimum of three years.
Posted in BioUtah News
Tagged teva pharmaceuticals
Comments Off on Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Teva Announces Appointment of Richard Francis as President and CEO
Kåre Schultz to Retire After a Transformative Five-Year Tenure Setting the Stage for an Exciting Future
